Last reviewed · How we verify
NCT06252454: INFURO
The Impact of Inhaled Furosemide and Perorally Administered Levodropropizine on Dyspnea in Patients With Respiratory Diseases
Phase 2/Phase 3 trial testing Furosemide 40 mg in Dyspnea in 102 participants. Status unknown.
1 December 2024
Quick facts
| Lead sponsor | University Hospital Hradec Kralove |
|---|---|
| Phase | Phase 2/Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | other |
| Enrollment | 102 |
| Start date | 27 February 2024 |
| Primary completion | 1 December 2024 |
| Estimated completion | 1 December 2025 |
| Sites | 1 location across Czechia |
Drugs / interventions tested
- Furosemide 40 mg — full drug profile →
- Levodropropizine (LEVODROPROPIZINE) — full drug profile →
- Placebo - saline — full drug profile →
Conditions studied
- Dyspnea — all drugs for Dyspnea →
Sponsor
University Hospital Hradec Kralove
Who can join
18 and older, any sex, with Dyspnea. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Safety and tolerability of inhaled furosemide
Time frame: 24 hour
Incidence of Treatment-Emergent Adverse Events (AE) will be measured and reported. Any deterioration of clinical status of the subject during the study procedure will be reported as AE, especially but not only bronchospasm, worsening of the dyspnea, hemodynamic deterioration and every other event requiring change of the treatment of the subject during the study procedures and within next 24 hours
Sponsor's own description
The goal of this monocentric double blinded cross over trial is to evaluate safety and tolerability of inhaled furosemide in patients with pulmonary diseases and dyspnea. The main question\[s\] it aims to answer are: * is inhaled furosemide safe and well tolerated? * is inhaled furosemide capable of dyspnea suppression and is there any additive effect of levodropropizine Participants will be given: * inhaled furosemide or placebo in double blinded cross over manner. Dyspnea severity and vital functions will be measured, adverse reactions monitored * all participants will receive levodropropizine open label. Dyspnea severity and vital functions will be measured, adverse reactions monitored
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06252454
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Furosemide 40 mg
Trials testing the same drug.
- NCT05916963 — Impact of Forced Diuresis on the Residual Fragment Rate After Flexible Ureteroscopy for Destruction of Kidney Stones Wit · Phase 3 · recruiting
- NCT03753204 — Salt-Sensitivity and Immunity Cell Activation · Phase 1, PHASE2 · active not recruiting
- NCT05270421 — Effect of Furosemide on ESWL Outcomes for Renal and Ureteral Calculi · Phase 3 · unknown
- NCT04982874 — Bioequivalence Study of Furosemide 40 mg Tablet in 24 Indonesian Healthy Volunteers · NA · completed
- NCT03837470 — Evaluation of Renal Sodium Excretion After Salt Loading in Heart Failure With Preserved Ejection Fraction · EARLY_PHASE1 · completed
Other recruiting trials for Dyspnea
Currently open trials in the same condition.
- NCT07386444 — Inspiratory Muscle Training for Breast Cancer Patients on Chemotherapy · NA · recruiting
- NCT06807983 — LUng and Cardiac Ultrasound for REspiratory Distress in ElDerly · NA · recruiting
- NCT07104578 — Evaluation of the Impact of Pleuropulmonary Ultrasound on the Diagnosis of Dyspnea · recruiting
- NCT07268859 — Effect of Fan Application in Preventing Ticagrelor-Associated Dyspnea · NA · recruiting
- NCT06556797 — Proof-of-concept Study on Dyspnea Analysis Via GapCO2 · recruiting
Other University Hospital Hradec Kralove trials
Trials by the same sponsor.
- NCT07415655 — Modulation of Cerebral Ischemia by Albumin · Phase 2 · not yet recruiting
- NCT03644641 — The Influence of Prone Position for Spinal Surgery on Visual Acuity · NA · not yet recruiting
- NCT06894927 — Hearing Screening in Adults Over 50 Years Old · NA · enrolling by invitation
- NCT05399602 — The Role of Neurofilament Light (NfL) in Patients With Hydrocephalus · NA · completed
- NCT06083233 — Role of Brain Specific Biomarkers in Hydrocephalus · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06252454 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital Hradec Kralove
- Last refreshed: 15 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06252454.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing